Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome

American Journal of Psychiatry

Volumn 155, Issue 6, 1998, Pages 751-760

  Buchanan, Robert W ^a   Breier, Alan ^b   Kirkpatrick, Brian ^b   Ball, Patricia ^b   Carpenter, William T ^b  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL;

ADULT; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENURESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SALIVATION DISORDER; SCHIZOPHRENIA; SEDATION; SYMPTOMATOLOGY; VERTIGO; VOMITING; XEROSTOMIA;

ADULT; AGE OF ONSET; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOUBLE-BLIND METHOD; EMPLOYMENT; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL ADJUSTMENT; TREATMENT OUTCOME;

EID: 0031746826     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Buchanan RW: Clozapine: efficacy and safety. Schizophr Bull 1995; 21:579-591
2. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
3. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
4. Kuoppasalmi K, Rimon R, Naukkarinen H, Lang S, Sandqvist A, Leinonen E: The use of clozapine in treatment-refractory schizophrenia. Schizophr Res 1993; 10:29-32
5. Lindenmayer J-P, Grochowski S, Mabugat L: Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994; 14:201-204
6. Lieberman JA, Safferman AZ, Pollack S, Syzmanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1744-1752
7. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20-26
8. Meltzer HY: Clozapine: is another view valid? (editorial). Am J Psychiatry 1995; 152:821-825
9. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827-832
10. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M: Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993; 27:341-347
11. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC: Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35:8-15
12. Carpenter WT Jr, Heinrichs DW, Wagman AMI: Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145:578-583
13. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr: The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989; 30:119-123
14. Fenton WS, McGlashan TH: Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 1992; 49:179-184
15. Conley R, Gounaris C, Tamminga C: Clozapine response varies in deficit versus non-deficit schizophrenic subjects. Biol Psychiatry 1994; 35:746-747
16. Spitzer RL, Williams JBW, Gibbon M, First MB: Instruction Manual for the Structured Clinical Interview for DSM-III-R (SCID). New York, New York State Psychiatric Institute, Biometrics Research, 1989
17. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
18. Andreasen NC: Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39:784-788
19. Breier A, Buchanan RW, Irish D, Carpenter WT Jr: Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 44:1145-1149
20. Hawk AB, Carpenter WT, Strauss JS: Diagnostic criteria and five-year outcome in schizophrenia: a report from the International Pilot Study of Schizophrenia. Arch Gen Psychiatry 1975; 32:343-347
21. Heinrichs DW, Hanlon TE, Carpenter WT Jr: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388-398
22. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
23. Cassady SL, Thaker GK, Summerfelt A, Tamminga CA: The Maryland Psychiatric Research Center scale and the characterization of involuntary movements. Psychiatry Res 1997; 70:21-37
24. Buchanan RW, Carpenter WT: Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 1994; 182:193-204
25. Crow TJ: The two-syndrome concept: origins and current status. Schizophr Bull 1985; 11:471-486
26. Umbricht DG, Lieberman JA, Kane JM: The clinical efficacy of clozapine in the treatment of schizophrenia. Reviews in Contemporary Pharmacotherapy 1995; 16:165-186
27. Rosenheck R, Charney D, Cramer J, Xu W, Thomas J, VA CSH 17 Study Group: A randomized, double-blind trial of rhe efficacy and cost-effectiveness of clozapine (abstract). Schizophr Res 1997; 24:188
28. Essock SM, Hargreaves WA, Covell NH, Goethe J: Antipsychotics in research and clinical settings: clozapine's effectiveness for patients in state hospitals; results from a randomized trial. Psychopharmacol Bull 1996; 32:683-697
29. Buchanan RW, Holstein C, Breier A: The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 1994; 36:717-725
30. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153:321-330
31. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao X-M: Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 1994; 55(9, suppl B):102-106